Negative findings from trials with NLY01 or deferiprone for Parkinson's disease - Author's reply

Lancet Neurol. 2024 Jun;23(6):559. doi: 10.1016/S1474-4422(24)00163-7.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antiparkinson Agents / therapeutic use
  • Clinical Trials as Topic
  • Deferiprone* / pharmacology
  • Deferiprone* / therapeutic use
  • Humans
  • Iron Chelating Agents / therapeutic use
  • Negative Results
  • Parkinson Disease* / drug therapy
  • Pyridones / therapeutic use